An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

  • sponsor
    Incyte Corporation
Updated on 23 November 2020
measurable disease
refractory follicular lymphoma


An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)



The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).


For more information, please contact Incyte Corporation at 1.855.463.3463 or visit

Condition Follicular Lymphoma
Clinical Study IdentifierTX151684
SponsorIncyte Corporation
Last Modified on23 November 2020


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 0 yrs?
Gender: Male or Female
Do you have Follicular Lymphoma?
Aged 18 or older
Histologically confirmed FL
Documented CD20+ FL
Relapsed or refractory to any prior rituximab-containing regimen
Previously treated with a maximum of 4 cancer-directed treatment regimens
At least 1 measurable lesion > 1.5 cm in at least 1 dimension by computed tomography (CT) or magnetic resonance imaging (MRI)
Subjects must be willing to undergo an incisional or excisional lymph node biopsy of accessible adenopathy or provide the most recent, available archived tumor biopsy
ECOG performance status of 0 to 2

Exclusion Criteria

Clinical evidence of transformation to a more aggressive subtype of lymphoma or Grade 3B FL
History of central nervous system lymphoma (either primary or metastatic)
Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug administration
Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug
Prior treatment with a selective phosphatidylinositol 3-kinase (PI3K) d inhibitor or a pan-PI3K inhibitor
Prior treatment with bendamustine (within 12 months of the start of study treatment)
Received prior obinutuzumab
Received rituximab within 4 weeks of study start
Prior treatment-related toxicities that have not resolved to = Grade 1 before the date of study drug administration date except for stable chronic toxicities (= Grade 2) not expected to resolve (eg, stable Grade 2 peripheral neurotoxicity)
Received any prior monoclonal antibody (except an anti-CD20 antibody) within 90 days before the date of study start
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (eg, subjects in whom re-administration with rituximab would be contraindicated for safety reasons)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note